Aplicaciones en ginecología de los antagonistas de lh-rh

José Ignacio Madero, Óscar Eduardo Guerra, Gabriel Barbosa, Carlos Morán, Pilar Gaitán, Mabel Ávila, Jesús Alberto Ruiz

Resumen


Las modificaciones a la LH-RH nativa produjeron la aparición de los análogos: agonistas cuyas aplicaciones en la medicina reproductiva han sido ampliamente estudiadas y los antagonistas de reciente estudio y aparición. Existen ciertas situaciones clínicas en las cuales lo que se necesita es una rápida supresión de la producción de las gonadotropinas endógenas, y por el efecto estimulador inicial del análogo no se logra. Los antagonistas causan una supresión inmediata de la producción de FSH y LH por un bloqueo competitivo de los receptores lo cual hace que su uso sea óptimo en los casos de inducción de ovulación mas técnicas de reproducción asistida. Otras de la indicaciones potenciales serían los casos en los que se requiere una supresión de la producción endógena de esteroides sexuales como el caso de la hiperplasia benigna de próstata, el cáncer de próstata y el cáncer de ovario, en los cuales ha demostrado una promisoria utilidad.

Palabras clave


LHRH; GnRH; Antagonistas de GnRH; Estimulación ovárica; gonadotropinas; tratamiento del cáncer; miomatosis uterina

Texto completo:

PDF

Referencias


Matsuo H, Baba Y, Nair R, et al. Structure of the porcine LH- and FSH-releasing hormone. Biochem Biophys Res Comm. 1971; 43: 1344-1339.

Burgus R, et al. Primary structure of the ovine hypothalamic luteinizing hormone releasing factor (LFR). Proc. Natl. Acad. Sci. USA. 1972; 69: 278.

Arimura A. The backstage story of the discovery of LHRH. Endocrinology 1991; 129: 1687-1689.

Shally A. Use of GnRH in preference to LH-RH terminology in scientific papers. Hum. Reprod. 2000; 15: 2059-2061.

Conn PM, Crowley WF. Jr. Gonadotrophin-releasing hormone and its analogues. N Engl J Med. 1991; 324: 93-103.

Loumaye E. The control of the endogenous secretion of luteinizing hormone by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum Reprod 1990; 5: 357-376.

Macnamee MC, Howles CM, Edwards RG. Short term luteinizing hormone-releasing hormone agonist treatment: prospective trial of a novel ovarian stimulation regimen for in vitro fertilization. Fertil Steril 1989; 52: 264-269.

Smitz J, Ron-El R, Tarlatzis BC. The use of gonadotrophin-releasing hormone agonist for in vitro fertilization and other assisted procreation techniques: experience from three centers. Hum Reprod 1992; 7(suppl 1): 49-66.

Loumaye E, Porchet HC, Beltrami V et al. Ovulation induction with recombinant human follicle-stimulating hormone and luteinizing hormone. En Filicori Marco y Flamigni Carlo (eds), Ovulation Induction. Basic Science and Clinical Advances. Elsevier Science, The Netherlands, pp. 227-236.

Edwards RG, Lobo R. and Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod. 1996; 11: 917-919.

Bajusz S, Kovacs M, Gazdag M, et al. Highly potent antagonist of LH-RH free of edematogenic effects. Proc. Natl Acad. Sci. USA, 1988; 85: 1637-1641.

The Ganirelix Dose-finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormones surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormones (Puregon). Hum Reprod 1998; 13: 3023-31.

Oberyé JJL, Mannaerts BMJL, Huisman JAM, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose- porportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 1999; 72: 1006-1012.

Reissmann TH, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, and Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995; 10: 1974-1981.

Reissmann T, Engel J, Kutscher B, et al. The LHRH antagonist Cetrorelix. Drugs Future 1994; 19: 228-237.

Pinski J, Yano T, Reissmann T, et al. Evaluation of the in vitro and in vivo activity of the L-,D,L- and D-Cit6 forms of the LHRH antagonist Cetrorelix(SB-75). Int. J. Peptide Protein Res. 1995; 45: 410-417.

Conn PM and Crowley WF. Gonadotropin releasing hormone and its analogs. N. Engl. J. Med. 1991; 324: 93-103.

Stojilkovic SS, Reinhart J. and Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr. Rev. 1994; 15: 462-499.

Kaiser UB, Conn PM, and Chin WW. Studies of gonadotropin-releasing hormone(GnRH) action using GnRH receptor-expressing pituitary cells line. Endocr. Rev. 1997; 18: 46-70.

Horn F, Bilezikjian LM, Perrin MH, et al. Intracellular responses to gonadotropin-releasing hormone in a clonal cell line of gonadotrope lineage. Mol. Endocrinol. 1991; 5: 347.

Stojilkovic SS. and Katt KJ. Expression and signal transduction pathway of gonadotropin releasing hormone receptors. Recent. Prog. Horm. Res. 1995; 50:161-205.

Ortmann O, Ansari-Pirsarai B, Bloh P, et al. Modulatory actions of progesterone on gonadotropin releasing hormone induced arachidonic acid liberation from perifused rat pituitary cells. Eur. J. Endocrinol. 1996; 135: 626-630.

Ortmann O, Felberbaum R, Eick F, et al. The GnRH antagonist Cetrorelix does not affect steroidogenesis of human granulosa lutein cells. Exp. Clin. Endocrinol. (Suppl.), 1998.

Naor Z. Signal transduction mechanisms of calcium mobilizing hormones: the case of gonadotropin releasing hormone. Endocr. Rev., 1990; 11: 326-353.

Ortmann O, Tilse B. and Emons G. Modulatory actions of estradiol and progesterone on phorbol esther-estimulated LH secretion from cultured rat pituitary cells. J. Steroid Biochem. Mol. Biol. 1992; 43: 619-627.

Behre HM, Kliesch S, Puhse G, et al. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively supressmserum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. J. Clin. Endocrinol. Metab. 1997; 82: 1403-1408.

Reissmann T, Schally AV, Bouchard P, Riethmuller H, Engel J. The LHRH antagonist Cetrorelix: a review. Hum Reprod Update 2000; 6: 322-331.

Duijkers IJM, Kippling C, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin releasing hormone antagonist Cetrorelix in healthy female volunteers, Human Reproduction, 1998; 13: 2392-2398.

Oberyé JL, Mannaerts BMJL, Kleijn HJ, Timmer CJ. Pharmakinetic and pharmacodynamic characteristics of Ganirelix (Orgalutran). Part I. Absolut bioavailability of 0.25 mg of Ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil. Steril. 1999; 72: 1001-1005.

Schmutlzer RK, Diedrich K. Basic and Clinical aspects of GnRH-agonist in reproduction. Int. J. Gynecol. Obstet. 1990; 32: 311-324.

Olivennes F, Álvarez S, Bouchard P, et al. The use of a GnRH antagonist(Cetrorelix(r)) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mgr. Hum.Reprod. 1998; 13: 2411-2414.

Olivennes F, Fanchin R, Bouchard P, et al. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: A pilot study. Hum Reprod. 1995; 10: 1382-1386.

Felberbaum R, Diedrich K. Ovarian stimulation for in vitro fertilization/intracitoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonist and antagonist. Hum. Reprod. 1999; 14: 207-221.

Sills ES, Levy DP, Moomjy M, et al. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Hum.Reprod. 1999; 14: 2230-2235.

Rongiéres-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin- releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum. Reprod. 1999; 14: 683-688.

Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective randomized controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-320.

Felberbaum RE, Albano C, Ludig M, et al and on behalf of the European Cetrorelix Study Group. Hum Reprod. 2000; 15: 1015-1020.

The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum.Rep. 2001; 16: 644-651.

Akman MA, Ereden HF, Tosun S, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum. Reprod. 2000; 15: 2145-2147.

Akman MA, Erden HF, Tosum SB, Bayasit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum. Reprod. 2001; 16: 868-870.

González-Barcena D, Banuelos Álvarez R, Pérez Ochoa E, et al. Treatment of uterine Leiomyomas with LHRH antagonist Cetrorelix. Hum. Reprod. 1997; 12: 2028-2035.

Felberbaum R, Germer U, Ludwid M, et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotropin releasing hormone antagonist Cetrorelix. Hum.Reprod. 1998; 13: 1660-1668.

Schally AV. LHRH Analogues: I. Their impact on the control of tumorigenesis. Peptides. 1999; 20: 1247-1262.

Emons G, and Schally AV. The use of luteinizing releasing hormone agonists and antagonist in gynecological cancers. Hum. Reprod. Update. 1994; 9: 1364-1379.


comments powered by Disqus

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2016 Revista Colombiana de Obstetricia y Ginecología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN Impreso       0034-7434 

ISSN Electrónico   2463-0225

https://doi.org/10.18597/issn.0034-7434